Ignite Creation Date:
2024-05-05 @ 4:45 PM
Last Modification Date:
2024-10-26 @ 9:23 AM
Study NCT ID:
NCT00307931
Status:
TERMINATED
Last Update Posted:
2011-08-31
First Post:
2006-03-24
Brief Title:
Certolizumab Pegol for Treatment of Adult Greek Patients With Moderate to Severe Crohns Disease Who Failed Infliximab
Sponsor:
UCB Pharma
Organization:
UCB Pharma
Study Overview
Official Title:
Certolizumab Pegol in the Treatment of Adult Greek Patients With Moderate to Severe Crohns Disease Who Have Been Previously Treated Successfully With Infliximab But Who Have Subsequently Lost Response or Developed Intolerance to Infliximab
Status:
TERMINATED
Status Verified Date:
2009-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Study was terminated early because of slow recruitment
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
An open-label multi-center single-cohort study to assess the safety and efficacy of certolizumab pegol for the treatment of signs and symptoms of active Crohns disease in Greek patients who have previously responded to infliximab but who no longer have a sustained response or became intolerant to infliximab
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| Eudract n - 2006-002027-16 | None | None | None |